In addition, a fixed-dose combination of the LAG-3 blocking antibody relatlimab and the PD-1 blocking antibody nivolumab, known as opdualag (Bristol Myers Squibb) approved by the FDA, has shown a promising improvement in PFS for patients with unresectable or metastatic melanoma (47). This evidence concerns the gene PDCD1 and metastatic melanoma.